StockNews.com Initiates Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)

Equities research analysts at StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

Navidea Biopharmaceuticals Price Performance

NAVB opened at $0.00 on Wednesday. The company has a market capitalization of $100,084.00, a P/E ratio of -0.02 and a beta of 1.47. Navidea Biopharmaceuticals has a twelve month low of $0.00 and a twelve month high of $0.15.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.